Date	Name	Title	Type	Shares Traded	Price Range
Oct 1, 2007	vagelos p roy	Director	Automatic Sell	11,560	n/a
Oct 2, 2007	shooter eric m	Director	Option Execute	10,000	7.66
Oct 2, 2007	shooter eric m	Director	Sell	10,000	18.30 - 18.37
Nov 2, 2007	mccorkle douglas s	Officer	Option Execute	6,209	8.50 - 9.49
Nov 2, 2007	mccorkle douglas s	Officer	Automatic Sell	6,209	21.00 - 21.03
Nov 5, 2007	brown michael s	Director	Automatic Sell	600	20.67 - 20.87
Nov 5, 2007	brown michael s	Director	Option Execute	10,000	7.91
Nov 5, 2007	brown michael s	Director	Automatic Sell	13,292	20.31 - 20.66
Nov 5, 2007	goldstein joseph l	Director	Option Execute	800	7.66
Nov 5, 2007	goldstein joseph l	Director	Automatic Sell	800	20.64 - 20.87
Nov 5, 2007	goldstein joseph l	Director	Option Execute	4,200	7.66
Nov 5, 2007	goldstein joseph l	Director	Automatic Sell	4,200	20.38 - 20.63
Nov 6, 2007	brown michael s	Director	Automatic Sell	6,108	19.42 - 20.08
Nov 20, 2007	roberts william	Officer	Acquisition (Non Open Market)	34,684	n/a
Nov 20, 2007	vagelos p roy	Director	Automatic Sell	138,737	n/a
Dec 12, 2007	gilman alfred g	Director	Disposition (Non Open Market)	2,000	n/a
Dec 17, 2007	gilman alfred g	Director	Disposition (Non Open Market)	1,500	n/a
Dec 17, 2007	goldberg murray a	Officer	Disposition (Non Open Market)	200	n/a
Dec 17, 2007	yancopoulos george	Officer	Acquisition (Non Open Market)	500,000	n/a
Dec 19, 2007	gilman alfred g	Director	Disposition (Non Open Market)	500	n/a
Showing 1-20 of 174 transactions Page: 1 2 3 4 5 6 7 8 9  See Next 20

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.